Navigation Links
Testosterone, Urine

ProductsTestosterone, Urine
Company ARUP Laboratories
Item Testosterone, Urine
Features 
Description ARUP Laboratories is a national reference laboratory and a worldwide leader in innovative laboratory research and development. ARUP offers an extensive test menu of highly complex and unique medical tests in clinical and anatomic pathology. Owned by the University of Utah, ARUP Laboratories' clients include more than half of the nation's university teaching hospitals and children's hospitals, major commercial laboratories, military and government facilities, and major clinics.
Info ARUP Laboratories
Customer Service: (800) 522-2787
Web site: http://www.aruplab.com

Related medicine products :

1. Testosterone, Adult Male
2. Testosterone, Bioavailable & Sex Hormone Binding Globulin (Includes Total Testosterone), Adult Male
3. Testosterone, Females or Children
4. Testosterone, Free & Total (Includes Sex Hormone Binding Globulin), Females or Children
5. Testosterone, Bioavailable & Sex Hormone Binding Globulin (Includes Total Testosterone), Females or Children
6. Testosterone, Free & Total (Includes Sex Hormone Binding Globulin), Adult Male
7. Clinitek 500 Urine Chemistry Analyzer
8. Clinitek Atlas Automated Urine Chemistry Analyzer (Rack)
9. Chemstrip 101 Urine Analyzer
10. Clinitek Atlas Automated Urine Chemistry Analyzer (Carousel)
11. Urisys 1100 Urine Analyzer
Other Medicine News:Health News:Most Kidney Donors Lead Long, Healthy Lives 2Health News:Most Kidney Donors Lead Long, Healthy Lives 3Health News:NBTY Reports First Quarter Results 2Health News:NBTY Reports First Quarter Results 3Health News:NBTY Reports First Quarter Results 4Health News:NBTY Reports First Quarter Results 5Health News:NBTY Reports First Quarter Results 6Health News:NBTY Reports First Quarter Results 7Health News:NBTY Reports First Quarter Results 8Health News:NBTY Reports First Quarter Results 9Health News:NBTY Reports First Quarter Results 10Health News:NBTY Reports First Quarter Results 11Health News:NBTY Reports First Quarter Results 12Health News:NBTY Reports First Quarter Results 13Health News:NBTY Reports First Quarter Results 14Health News:NBTY Reports First Quarter Results 15Health News:NBTY Reports First Quarter Results 16Health News:Medical College of Wisconsin recognized for AIDS intervention research 2Health News:Covance Reports Fourth Quarter and Full-Year 2008 Results 2Health News:Covance Reports Fourth Quarter and Full-Year 2008 Results 3Health News:Covance Reports Fourth Quarter and Full-Year 2008 Results 4Health News:Covance Reports Fourth Quarter and Full-Year 2008 Results 5Health News:Covance Reports Fourth Quarter and Full-Year 2008 Results 6Health News:Covance Reports Fourth Quarter and Full-Year 2008 Results 7Health News:Covance Reports Fourth Quarter and Full-Year 2008 Results 8Health News:Covance Reports Fourth Quarter and Full-Year 2008 Results 9Health News:Covance Reports Fourth Quarter and Full-Year 2008 Results 10Health News:Covance Reports Fourth Quarter and Full-Year 2008 Results 11Health News:Covance Reports Fourth Quarter and Full-Year 2008 Results 12Health News:Toxic Causation Training Day for Attorneys 2
Breaking Medicine Technology:Within3 Expands into Mobile Applications 2Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 2Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 3Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 4Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 5Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 6Onyx Pharmaceuticals to Webcast Analyst Briefing on Development Program 2RecoverCare and MedaSTAT USA Complete Transaction 53601 1RecoverCare and MedaSTAT USA Complete Transaction 53601 2RecoverCare and MedaSTAT USA Complete Transaction 53601 3BMP Sunstone Divests Ownership Stake in Alliance BMP Limited 53599 1BMP Sunstone Divests Ownership Stake in Alliance BMP Limited 53599 2AlphaRx and Venturepharm Announce Collaboration Agreement 53597 1AlphaRx and Venturepharm Announce Collaboration Agreement 53597 2